The effect of medroxyprogesterone acetate on gonadotropin secretion in girls with precocious puberty.
Plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) as detected by radioimmunoassay have been found to be present in prepubertal children and show a gradual rise until the onset of puberty. Children with idiopathic true precocious puberty have plasma gonadotropin levels which are appropriate for their advanced degree of sexual development. A potent progestational agent, 6-methyl-17-hydroxyprogesterone acetate or medroxyprogesterone has been used in the treatment of precocious puberty and will suppress its physical manifestations. In this study the effect of medroxyprogesterone on gonadotropin levels was investigated in seven girls with true precocious puberty. Plasma LH values were found to be significant lower in patients receiving this agent than in a group of normal prepubertal girls. FSH values did not differ from the control group. One patient was evaluated prior to treatment and showed decreasing levels of LH after therapy was begun. These data suggest that medroxyprogesterone may act on the pituitary-hypothalamic axis to suppress the pubertal levels of LH.
D000328:Adult; D002648:Child; D002675:Child, Preschool; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D008297:Male; D008525:Medroxyprogesterone / Q000494:pharmacology / Q000627:therapeutic use*; D011629:Puberty, Precocious / Q000097:blood / Q000188:drug therapy*; D011863:Radioimmunoassay
D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone